Trials / Unknown
UnknownNCT06214117
Comparison of Emergence Delirium: Remimazolam vs Sevoflurane Anesthesia
Comparison of Emergence Agitation in Children Following Tonsillectomy and Adenoidectomy Under Remimazolam or Sevoflurane General Anesthesia
- Status
- Unknown
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University · Academic / Other
- Sex
- All
- Age
- 3 Years – 6 Years
- Healthy volunteers
- Not accepted
Summary
Emergence delirium can lead to a range of clinical problems and is even associated with short-term behavioral changes in children. Pediatric ear, nose, and throat (ENT) surgery is one of the most common surgical types for postoperative delirium in children. Sevoflurane anesthesia is also a known cause of postoperative delirium. Therefore, this study aims to explore whether there is a difference in the incidence of postoperative delirium in children under remimazolam general anesthesia and sevoflurane anesthesia.
Detailed description
children aged 3-6 years old were randomly and equally allocated into two groups: Group R remimazolam, Group S with sevoflurane, respectively.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Remimazolam | Anesthesia induction:intravenous Fentanyl 2-3 μg/kg, remimazolam 0.3-0.5 mg/kg and Rocuronium 0.6mg/kg; Maintenance of anesthesia:Remimazolam will infuse initially at a rate of 2 mg/kg/h (1-3 mg/kg/h), and remifentanil will administer at an initial infusion rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min). |
| DRUG | Sevoflurane | Anesthesia induction: Anesthesia will induce with 8% sevoflurane in 100% oxygen at flow rate of 6 L/min, and then intravenous fentanyl (2-3 μg/kg) and rocuronium (0.6 mg/kg); Maintenance of anaesthesia: Anesthesia depth will maintain at 1-1.5 minimum alveolar concentration (MAC), and remifentanil was infuse at an initial rate of 0.25 μg/kg/min (0.1-0.5 μg/kg/min). |
Timeline
- Start date
- 2024-02-01
- Primary completion
- 2025-02-01
- Completion
- 2025-03-01
- First posted
- 2024-01-19
- Last updated
- 2024-01-19
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06214117. Inclusion in this directory is not an endorsement.